Test Detail
Hepatitis B Surface Antibody
Back to Test Directory| Test Description |
|
||||
|---|---|---|---|---|---|
| Qualitative and quantitative determination of antibody to hepatitis B surface antigen. | |||||
| Performed | Avg. Turnaround Time | Method | |||
| Coralville, 8 a.m. - 5 p.m., M-F |
5 - 7 business days | Chemiluminescent Immunoassay (CLIA) - DiaSorin | |||
| Fee | CPT Code(s) | ||||
| $21.42 | 86706 | ||||
| Specimen Requirements | |||||
| Specimen Type: | Minimum 1 mL Serum | ||||
| Collection Instructions: |
Blood should be collected aseptically by venipuncture, allowed to clot, and the serum separated from the clot as soon as possible.
Red Top Tube: centrifuge and transfer serum to a secondary tube. |
||||
| Shipping: | |||||
| Specimens should be stored and shipped under the same conditions. Wrap specimen container in absorbent material and place inside a biohazard bag. Transport specimen with cold pack. Ship to the Coralville location. | |||||
| Temperature and Stability: | Refrigerate (2-8 degrees C); stable for up to 7 days. Freeze (-20 degrees C); stable for more than 7 days. | ||||
| Rejection Criteria: |
Specimens will be rejected if received under these conditions: Plasma, CSF. Grossly hemolyzed or lipemic samples as well as samples containing particulate matter or exhibiting obvious microbial contamination should not be tested. Specimens not received in the correct temperature ranges stated under "Temperature and Stability" will be rejected. |
||||
| Expected Results: | |||||
| Negative or Positive and value in mIU/mL | |||||
| Comments | |||||
| For a positive result: CDC guidelines currently state that a value of >=10 mIU/mL indicates recovery from acute or chronic hepatitis B virus infection or acquired immunity from HBV vaccination. This assay does not differentiate between a vaccine-induced immune response and an immune response induced by infection with HBV. For a negative result: CDC guidelines currently state that a value of <10.00 mIU/mL indicates a lack of recovery from acute or chronic hepatitis B or inadequate immune response to HBV vaccination. | |||||
| Alternate Names | |||||
| HBV surface antibody, HBsAb, Hepatitis B Immunity | |||||
